The Jagannathan lab at Stanford University focuses on human immunology of infectious diseases.
The main focus of our group is studying naturally acquired immunity to malaria, novel interventions to prevent malaria in endemic settings, and the immunologic benefits of malaria control interventions.
Our group has also been drawn into the COVID-19 response.
Along with Dr. Upi Singh in the Division of Infectious Diseases and Geographic Medicine, Dr. Jagannathan is leading a trial of a novel therapeutic – Peginterferon Lambda (Lambda), a type III interferon - for the treatment of SARS-CoV-2 infected outpatients (NCT 04331899).
Dr. Jagannathan’s lab is also studying the impact of Lambda on the host immune response to SARS-CoV-2.